针对临床II/III期食管鳞状细胞癌的根治性放化疗联合挽救治疗的单臂确证性研究(JCOG0909研究)
这项单臂多中心试验纳入96例临床II/III期食管鳞癌患者,评估改良根治性放化疗联合挽救治疗。94例可评估患者3年总生存率为74.2%(90%CI 65.9%-80.8%),完全缓解55例(59%)。作者认为该方案放化疗相关毒性较低且总生存良好,是有前景的新治疗选择。
要点
- 94例可评估患者3年总生存率为74.2%(90%CI 65.9%-80.8%)
- 完全缓解55例(59%),挽救性内镜切除5例(5%),挽救性手术25例(27%)
- 挽救性手术R0切除19例(76%),长期随访中3级晚期毒性9例(9.6%)
核心结论
- 根治性放化疗联合挽救治疗放化疗相关毒性较低且总生存良好,作者认为这是局部晚期食管癌有前景的新治疗选择。
研究设计与样本
- 单臂多中心试验(JCOG0909),纳入临床II/III期食管癌(国际抗癌联盟第六版,非T4)患者。
- 化疗为顺铂(第1、29天75 mg/m2)联合5-氟尿嘧啶(第1-4天和第29-32天1000 mg/m2/d),放疗总剂量50.4 Gy。
- 疗效良好者接受1至2个额外周期化疗;残留或复发疾病按特定标准行挽救性内镜切除或挽救性手术。
- 主要终点为3年总生存率,计算样本量95例,单侧α为5%,把握度80%,预期和阈值3年总生存率分别为55%和42%。
主要发现
- 共入组96例患者,94例纳入疗效分析。
- 完全缓解55例(59%);挽救性内镜切除5例(5%),挽救性手术25例(27%)。
- 挽救性手术R0切除19例(76%)。
- 挽救性手术后早期手术并发症3级或4级5例(20%);长期随访中3级晚期毒性9例(9.6%)。
- 3年总生存率为74.2%(90%置信区间65.9%-80.8%)。
关键数值与推荐
- 化疗:顺铂第1、29天75 mg/m2;5-氟尿嘧啶第1-4天和第29-32天1000 mg/m2/d。
- 放疗总剂量50.4 Gy;疗效良好者接受1至2个额外周期化疗。
- 残留或复发疾病按特定标准行挽救性内镜切除或挽救性手术。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Definitive chemoradiotherapy (CRT) is the standard treatment for patients with locally advanced esophageal cancer (EC) who refuse surgery as the initial therapy. However, poor survival, a high incidence of late toxicities, and severe complications after salvage surgery remain issues to be resolved. This single-arm multicenter trial (JCOG0909) aimed to confirm the efficacy of CRT modifications, including salvage treatment for reducing CRT-related toxicities and facilitating salvage treatment for improved survival. METHODS AND MATERIALS: Patients with clinical stage II/III EC (International Union Against Cancer sixth edition, non-T4) were eligible. Chemotherapy comprised cisplatin (75 mg/m2 on days 1 and 29) and 5-fluorouracil (1000 mg/m2/d on days 1-4 and 29-32). Radiation therapy was administered at a total dose of 50.4 Gy. Good responders received 1 to 2 additional cycles of chemotherapy. For residual or recurrent disease, salvage endoscopic resection or salvage surgery was performed based on specific criteria. The primary endpoint was 3-year overall survival (OS). The calculated sample size was 95 patients, with a 1-sided alpha of 5% and a power of 80%. The expected and threshold 3-year OS were 55% and 42%, respectively. RESULTS: Overall, 96 patients were enrolled, and 94 were included in the efficacy analysis. A complete response was achieved in 55 patients (59%). Salvage endoscopic resection and salvage surgery were performed in 5 (5%) and 25 patients (27%), respectively. R0 resection by salvage surgery was achieved in 19 patients (76%). Five patients (20%) showed grade 3 or 4 early operative complications, and 9 patients (9.6%) showed grade 3 late toxicities during the long-term follow-up. The 3-year OS was 74.2% (90% confidence interval, 65.9%-80.8%). CONCLUSION: The combination of definitive CRT and salvage treatment has lower CRT-related toxicities and yields good OS, thus making it a promising novel treatment option for patients with locally advanced EC.
引用
- Takeuchi H, Ito Y, Machida R, et al. A Single-Arm Confirmatory Study of Definitive Chemoradiation Therapy Including Salvage Treatment for Clinical Stage II/III Esophageal Squamous Cell Carcinoma (JCOG0909 Study). Int J Radiat Oncol Biol Phys. 2022. PMID: 35932949. doi:10.1016/j.ijrobp.2022.07.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。